Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
1.35
-0.12 (-8.16%)
At close: Sep 25, 2023, 4:00 PM
1.50
+0.15 (11.11%)
Pre-market: Sep 26, 2023, 6:46 AM EDT
-8.16%
Market Cap 125.16M
Revenue (ttm) 8.56M
Net Income (ttm) -111.76M
Shares Out 92.71M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 417,439
Open 1.45
Previous Close 1.47
Day's Range 1.35 - 1.48
52-Week Range 1.13 - 3.71
Beta 1.20
Analysts Strong Buy
Price Target 9.33 (+591.11%)
Earnings Date Nov 8, 2023

About ABSI

Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 22, 2021
Employees 193
Stock Exchange NASDAQ
Ticker Symbol ABSI
Full Company Profile

Financial Performance

In 2022, Absci's revenue was $5.75 million, an increase of 20.18% compared to the previous year's $4.78 million. Losses were -$104.90 million, 1.61% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 591.11% from the latest price.

Price Target
$9.33
(591.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen

VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day ...

4 days ago - GlobeNewsWire

Absci to Host R&D Day on October 4, 2023

VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on We...

19 days ago - GlobeNewsWire

Biotech company Absci lays off 30 employees, about 15% of staff

Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.

20 days ago - GeekWire

Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo...

4 weeks ago - GlobeNewsWire

Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results

Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover afford...

6 weeks ago - GlobeNewsWire

Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer

Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth

6 weeks ago - GlobeNewsWire

Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced that leading researchers at the California Institute of Te...

6 weeks ago - GlobeNewsWire

Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

7 weeks ago - GlobeNewsWire

Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit

VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

3 months ago - GlobeNewsWire

Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his...

3 months ago - GlobeNewsWire

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate

4 months ago - GlobeNewsWire

University of Oxford's Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Absci will apply its generative AI platform to The Kennedy Institute's immunology biorepository to speed the discovery and development of multiple therapies Absci will apply its generative AI platform...

4 months ago - GlobeNewsWire

Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upco...

6 months ago - GlobeNewsWire

Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI

6 months ago - GlobeNewsWire

Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation

VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually i...

6 months ago - GlobeNewsWire

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually i...

7 months ago - GlobeNewsWire

Absci Takes Its Generative AI Antibody Design Platform To Europe

Generative AI technology, like ChatGPT, is disrupting many industries including biopharma. For example, Absci is using AI to design & validate de novo antibodies.

7 months ago - Forbes

Absci to Participate in the 43rd Annual Cowen Health Care Conference

VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

7 months ago - GlobeNewsWire

St. John's Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies

Absci's generative AI and wet lab capabilities combined with St. John's Cancer Institute's molecular database of cancer patient specimens will accelerate the development of immunotherapies.

8 months ago - GlobeNewsWire

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci's scientific leadership in bio...

8 months ago - GlobeNewsWire

Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

9 months ago - GlobeNewsWire

Absci to Participate in the Berenberg Discover AI Seminar

VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

10 months ago - GlobeNewsWire

Absci to Participate in the Piper Sandler Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...

11 months ago - GlobeNewsWire

Absci Reports Third Quarter 2022 Financial Results

Milestone achievement and progress continues in previously announced Merck collaboration

11 months ago - GlobeNewsWire

Absci to Participate in the Stifel Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data...

11 months ago - GlobeNewsWire